Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis

References

• Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012;119:571–580.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Adv Endocrinol Metabolism 2013;4:151–169.
   PubMedGoogle Scholar
• Glanville J, Patterson J, McCool R, et al. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 2014;14:7.
   PubMed Web of Science ®Google Scholar
• Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012;119:2179–2188.
   PubMed Web of Science ®Google Scholar
• Pielen A, Feltgen N, Isserstedt C, et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 2013;8(10):e78538.
   Web of Science ®Google Scholar
• Lucentis summary of product characteristics. London, UK: European Medicines Agency, 2013.
   Google Scholar
• Lucentis prescribing information. Silver Spring, MD: US Food and Drug Administration, 2013.
   Google Scholar
• American Academy of Ophthalmology Retina Panel. Preferred practice pattern guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology, 2008.
   Google Scholar
• Age-related macular degeneration (management recommendations). San Francisco, CA: International Council of Ophthalmology, 2011.
   Google Scholar
• Royal College of Ophthalmologists. Age-related macular degeneration: guidelines for management. London, UK: Royal College of Ophthalmologists, 2013.
   Google Scholar
• Menon G, Walters G. New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy. Eye 2009;23(Suppl. 1):S1–7.
   Google Scholar
• Belkin M, Kalter-Leibovici O, Chetrit A, et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2013;155:404.
   PubMed Web of Science ®Google Scholar
• Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012;153:209–213, e2.
   PubMed Web of Science ®Google Scholar
• Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling? Eye 2012;26:933–936.
   PubMed Web of Science ®Google Scholar
• Skaat A, Chetrit A, Belkin M, et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012;153:214–221, e1.
   Google Scholar
• Keenan TD, Kelly SP, Sallam A, et al. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 2013;97:1168–1172.
   PubMed Web of Science ®Google Scholar
• Claessen H, Genz J, Bertram B, et al. Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 2012;27:519–524.
   PubMed Web of Science ®Google Scholar
• Sloan FA, Hanrahan BW. The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol 2014;132:456–463.
   PubMed Web of Science ®Google Scholar
• Cackett P, Borooah S, Gavin M, et al., Scotland AMD study group. Intravitreal ranibizumab treatment of wet macular degeneration in SE Scotland – effect on blindness rates and 5 year follow up data. Invest Ophthalmol Vis Sci 2013;54:372.
   Google Scholar
• Eylea summary of product characteristics. London, UK: European Medicines Agency, 2013.
   Google Scholar
• Eylea prescribing information. Silver Spring, MD: US Food and Drug Administration, 2013.
   Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171–185.
   PubMed Web of Science ®Google Scholar
• Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol 2011;48:1656–1665.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 2011;25:661–672.
   PubMed Web of Science ®Google Scholar
• Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782–790.
   PubMed Web of Science ®Google Scholar
• Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887–895, e1.
   Google Scholar
• CATT research group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398.
   Google Scholar
• Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflammation 2013;2013(943409).
   Google Scholar
• Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116:1225, e1.
   Google Scholar
• Shah CP, Garg SJ, Vander JF, et al. Post-Injection Endophthalmitis Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118:2028–2034.
   Google Scholar
• Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology 2013;120:1100–1101, e1–5.
   Google Scholar
• Pharmacovigilance Risk Assessment Committee (PRAC). London, UK: European Medicines Agency, 2013.
   Google Scholar
• Fukami T, Kitahashi M, Sato E, et al. [Six cases of sterile endophthalmitis developed consecutively after intravitreal injection of bevacizumab]. Nihon Ganka Gakkai Zasshi 2011;115:706–710.
   PubMedGoogle Scholar
• Goldberg RA, Flynn HW, Jr., Miller D, et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology 2013;120:1448–1453.
   PubMed Web of Science ®Google Scholar
• Royal College of Ophthalmologists. Potential bevacizumab-related sterile endophthalmitis cases – update, 15 March 2012. London, UK: Royal College of Ophthalmologists, 2012.
   Google Scholar
• Cavalcante LL, Cavalcante ML, Murray TG, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 2010;4:519–524.
   PubMedGoogle Scholar
• Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609–1614.
   PubMed Web of Science ®Google Scholar
• Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601–605.
   PubMed Web of Science ®Google Scholar
• Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395–1399.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Walton R, Simpson JM, et al. Fight Retinal Blindness! Project Investigators. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci 2013;54:5754–5760.
   Google Scholar
• Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye 2012;26:1517–1526.
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Flynn HW, Jr., et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662–668.
   PubMed Web of Science ®Google Scholar
• Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879–882.
   PubMed Web of Science ®Google Scholar
• Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina 2014;34:18–23.
   PubMed Web of Science ®Google Scholar
• Kiss S, Dugel PU, Wilson K, et al. Treatment patterns and associated costs of anti-VEGF therapy for neovascular age-related macular degeneration. Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Orlando, FL, USA, 2014; Poster 5596.
   Google Scholar
• Ang GS, Varga Z, Shaarawy T. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol 2010;94:1571–1576.
   PubMed Web of Science ®Google Scholar
• Cao H, Zhang L, Li L, et al. Risk factors for acute endophthalmitis following cataract surgery: a systematic review and meta-analysis. PLoS One 2013;8:e71731.
   Google Scholar
• Eifrig CW, Flynn HW, Jr., Scott IU, et al. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995–2001). Ophthalmic Surg Lasers 2002;33:373–378.
   PubMedGoogle Scholar
• Kernt M, Kampik A. Endophthalmitis: pathogenesis, clinical presentation, management, and perspectives. Clin Ophthalmol 2010;4:121–135.
   PubMedGoogle Scholar
• Julien S, Biesemeier A, Taubitz T, et al. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 2014;98:813–825.
   PubMed Web of Science ®Google Scholar
• Murinello S, Mullins RF, Lotery AJ, et al. Fc gamma receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration. Invest Ophthalmol Vis Sci 2014;55:247–258.
   PubMed Web of Science ®Google Scholar
• Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875–912.
   PubMed Web of Science ®Google Scholar
• Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 2011;31:2032–2036.
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Googe JM, Jr., Stockdale CR, et al. Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581–1583.
   Google Scholar
• Storey P, Dollin M, Pitcher J, et al. Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 2014;121:283–289.
   Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654–661.
   PubMed Web of Science ®Google Scholar
• Dollin M, Storey P, Vander J, et al. The effect of a “no talking” policy during intravitreal injection on post-injection endophthalmitis. Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Orlando, FL, USA, 2014; Abstract 587.
   Google Scholar
• Dreyer NA, Velentgas P, Westrich K, et al. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Managed Care Pharmacy 2014;20:301–308.
   PubMed Web of Science ®Google Scholar